The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
News|Articles|November 2, 2023
Targeting Automation Advances to Meet Industry Needs (AAPS PharmSci 360)
Author(s)Feliza Mirasol
Hollie Barton, senior director, Chromatographic Services, for the PPD clinical research business of Thermo Fisher Scientific, reviews the company’s latest moves in targeting automation.
Advertisement
Hollie Barton, senior director, Chromatographic Services, for the PPD clinical research business of Thermo Fisher Scientific, spoke with Pharmaceutical Technology® at AAPS PharmSci 360 about how PPD is targeting automation advances to address the bio/pharma industry’s need to move more efficiently and quickly, especially when adding staff alone is not always the answer.
“2023, through the latter part of 2023, and into 2024 have been by far our biggest investment in information technology (IT),” Barton says. “We are looking at automation from a front-end to the back-end—fully automated workflows—and, so, it's pretty exciting to see some of the robotics that are showing up in the laboratories.”
Barton also expresses enthusiasm about how PPD is also adding teams, such as an informatics team, which functions between the operations group and the IT group, bridging the gap between the two groups. Having the informatics group in place results in the addition of analytic dashboards, according to Barton.
“We're using those dashboards to hone in on ensuring we are right first-time [allowing us to] focus on quality and ensure that errors that are repetitive are being addressed, and that is being done through process improvements using that automation,” Barton states.
The company has also added a group called PPI—practical process improvement. “That team is looking at efficiencies and evaluating automation, while following the workflow of the departments,” she says. Even with just the smallest changes recommended by the PPI team, such as reducing the number of steps between work stations or work areas, the company is already seeing improvements, she notes.
AAPS PharmSci 360 ran Oct. 22–25 in Orlando, Fl.
View Barton’s video interviews on
Advertisement
Related to this article
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
The IMA Pharmaceutical and MedTech divisions will be highlighting the TILE-X fill-finish line, a new VPHP BioIndicator, X-PEN autoinjector platform, and a range of machines from its IMA Active, IMA Life, IMA Safe, and IMA BFB divisions at the CPHI Milan event.
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss navigating CMC requirements for new modalities and AI’s involvement in CMC.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement